{"id":7419,"date":"2023-10-16T16:54:03","date_gmt":"2023-10-16T14:54:03","guid":{"rendered":"https:\/\/www.positrigo.com\/positrigo-opens-us-subsidiary-to-benefit-from-promising-market-developments\/"},"modified":"2023-10-16T16:54:03","modified_gmt":"2023-10-16T14:54:03","slug":"positrigo-opens-us-subsidiary-to-benefit-from-promising-market-developments","status":"publish","type":"post","link":"https:\/\/www.positrigo.com\/en-gb\/positrigo-opens-us-subsidiary-to-benefit-from-promising-market-developments\/","title":{"rendered":"Positrigo opens US subsidiary to benefit from promising market developments"},"content":{"rendered":"\n\n\n\n\n\n<section id=\"res-header-image-block_619ca098a7574\" class=\"res-block res-header-image alignfull\">\n  <div class=\"res-header-img-outside mb-4\" data-aos=\"res-fadeIn\">\n\t<div class=\"res-header-height\">\n\t\t\n\t\n\t  <style> \n\t\t  @media only screen and (min-width: 970px) {\n\t\t\t #res-header-image-block_619ca098a7574.res-header-image .layout-1.header-img-height { height: 70vh;}  \n\t\t\t #res-header-image-block_619ca098a7574.res-header-image .layout-1 .res-header-image-vertical-center { top: 72%;} \n\t\t\t   \n\t\t  }\n\t\t  @media only screen and (max-width: 970px) {  \n\t\t\t#res-header-image-block_619ca098a7574.res-header-image .layout-1.header-img-height { height: 55vh;} \n\t\t\t#res-header-image-block_619ca098a7574.res-header-image .layout-1 .res-header-image-vertical-center { top: 55%;} \n\t\t\t    \n\t\t\t  \t\t  }\n\t\t   \n\t\t\t  @media only screen and (min-width: 1280px) {\n\t\t\t\t\t\t\t\t#res-header-image-block_619ca098a7574.res-header-image .layout-1 h1 {font-size: 200%; line-height: 105%;}\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t\t  }   \n\t\t \t  <\/style> \n\t\t\n\t  <div class=\"layout-1 jarallax header-img-height\" data-speed=\"0.6\" style=\"background-color: #fff;\">\n\t\t  \n\t\t\t\t<div class=\"res-header-image-vertical-center\">\n\t\t\t\t\t<div class=\"container-fluid\">\n\t\t\t\t\t\t\n\t\t\t\t\t\t<div class=\"sloganBox\">\n                           <div class=\"row\">\n                             <div class=\"col col-md-10 text-left\">\n\t\t\t\t\t\t\t\t <div class=\"sloganbox-background \" data-aos=\"res-fadeIn\">\n\t\t\t\t\t\t\t\t \n                                \t\n\t\t\t\t\t\t\t\t \n                                  \n\t\t\t\t\t\t\t\t \t<h2>Positrigo opens US subsidiary<\/h2>\n                                \t\t\t\t\t\t\t\t \n                                \t\n\t\t\t\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\t\t \t\t\t\t\t\t\t\t \t\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t                 <\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\n                                            <img decoding=\"async\" class=\"jarallax-img img-fluid\" src=\"https:\/\/www.positrigo.com\/wp-content\/uploads\/2023\/10\/IMG_7412-1920x1080.jpg\"  style=\"opacity: 0.8;\" alt=\"\"\/>\n                    \t\t  \n\t\t\t\t\n\t\t   <\/div>\n\t\t\t \n\t \n\n\n\t\t<\/div>\n\t<\/div>\n<\/section>\t\n\n\n\n<section id=\"res-txt-block_619ca0bca7575\" class=\"res-block res-txt layout01 p-no\" style=\"background: transparent;\">\n  <div class=\"inner-container container-off\" data-aos=\"res-fadeIn\">\n \n\t\t  \n\t\t \t  \n      \n      <div class=\"layout-1 txt-section\">\n\t\t<div class=\"row\">\t\n\t\t\t\n\t\t\n\t\t\t<div class=\"col-md-10 var-1spalten text-left\">\n\t\t\t\t\n\t\t\t\t<div class=\"txt-title-field\">\n\t\n\t\t\t\t\t\n\n\t\t\t\t  \n\t\t\t\t\t<h2>Positrigo opens US subsidiary to benefit from promising market developments<\/h2>\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t<div class=\"txt-textfield postContent pt-md-0\">\n\t\t\t\t\t\t\t\t\t\t  <p>October 16, 2023<\/p>\n<p><strong>Positrigo prepares for the US launch of its dedicated brain PET system NeuroLF by incorporating its US subsidiary. The US market experiences great momentum for brain Positron Emission Tomography (PET) due to the availability of disease-modifying therapies for Alzheimer\u2019s disease (AD) and the recent announcement by the U.S. Centers for Medicare &amp; Medicaid Services (CMS) to reimburse non-invasive imaging tests called amyloid PET.<\/strong><\/p>\n<p>Positrigo, a Swiss based company developing nuclear medical imaging devices to advance functional brain imaging, today announced the incorporation of its wholly owned US subsidiary. \u201cThe US is our first and most important market we want to penetrate after receiving FDA clearance for our dedicated brain PET system\u201d, states <strong>Dr. Stefan Bircher<\/strong>, Positrigo\u2019s Chief Commercial Officer and President of Positrigo Inc. \u201cBeside the significant size of the US market, other important conditions like the availability of disease-modifying therapies for AD patients and the reimbursement of brain PET scans exist which allow for a successful adoption of our NeuroLF system.\u201d.<\/p>\n<p>The two co-founders <strong>Dr. Jannis Fischer<\/strong> (CEO) and <strong>Dr. Max Ahnen<\/strong> (COO) further explain: \u201cWith the formation of our US subsidiary, we want to create the required structure and develop the necessary resources to capture the promising US market potential. It is very exciting to witness not only the successful development of our first product but also the expansion of our company into new markets.\u201d<\/p>\n<p><strong>Ron Lissak<\/strong> has been appointed as Executive Vice President and General Manager of Positrigo Inc. He is a medical imaging veteran and brings a wealth of experience in the nuclear medicine arena and an ever-growing network to Positrigo.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t <div class=\"txt-textfield-btns pt-2 \">\n\t\t\t\t\t\t  \n\t\t\t\t\t<\/div> \n\t\t\t\t\n\t\t\t\t\t\t\n\t\n\t\t\t\t<\/div>\n\n\t\t \n\t\t\t\n\t\t\t\n\t\t\t\n\n\t\t\t\t\t\n\t\t <\/div> \t\n\t\t<\/div>\n\t \n\t  \n \n \n\t<\/div>\n<\/section>\n\n\n\n\n\n<section id=\"res-text-bild-block_6452208b9f65f\" class=\"res-block res-text-bild layout01 py-1\" style=\"background: transparent;\">\n  <div class=\"inner-container container-off\" data-aos=\"res-fadeIn\">\n\n\t\t\t  <style>\n\t\t\t @media only screen and (min-width: 970px) {\n\t\t\t  #res-text-bild-block_6452208b9f65f.res-text-bild .layout-1 .txt-imagebox.offset-md-1 {margin-left: 3%;}\n\t\t\t  #res-text-bild-block_6452208b9f65f.res-text-bild .layout-1 .txt-box.offset-md-1 {margin-left: 3%;}\n\t\t\t}\n\t\t\t \n\t\t  <\/style>\n\n\n        <div class=\"layout-1 row \">\n\t\t\t<div class=\"col-md-7 txt-box \">\n\n\n\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\n\n\t\t\t\t <div class=\"txt-text postContent pt-2 pt-md-2\">\n\t\t\t\t\t\t\t\t\t\t  <p><strong><em>\u201cIt is very exciting to be part of this motivated team and I am looking forward to leading and managing the growth of Positrigo in the US.\u201d<\/em><\/strong><\/p>\n<p><em>Ron Lissak, EVP &amp; GM of Positrigo Inc.<\/em><\/p>\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t\n\t\t\t\t<\/div>\n\n\n\t\t\t<\/div>\n\n\t\t\t<div class=\"col-md mb-2 mt-md-1 txt-imagebox offset-md-1\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"750\" src=\"https:\/\/www.positrigo.com\/wp-content\/uploads\/2023\/10\/Ron-Lissak-1000x750.jpg\" class=\"img-fluid w-100 txt-img\" alt=\"\" \/>\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\n\n\t\n\t<\/div>\n<\/section>\n\n\n\n\n<p><\/p>\n\n\n\n<p><strong><strong>Improved Amyloid PET reimbursement in the US<\/strong> <\/strong><\/p>\n\n\n\n<p>The U.S. Centers for Medicare and Medicaid Services (CMS) announced on October 13, 2023 that it has lifted its coverage limit of one beta-amyloid PET scan per lifetime for patients with AD. This decision will significantly increase accessibility to brain PET scans and comes in the wake of recent U.S. Food and Drug Administration (FDA) approvals of the first drugs to treat AD \u2013 monoclonal antibodies that target brain amyloid plaque deposits. Medicare coverage decisions will now be made by local Medicare Administrative Contractors (MACs).<\/p>\n\n\n\n<p>Amyloid PET scans are a key diagnostic tool to enabling clinicians to identify and confirm the presence of amyloid plaques \u2013 one of the hallmarks of the AD diagnosis \u2013 in the brains of patients and thus ensure appropriate treatment. While methods other than amyloid PET for identifying pathologic brain amyloid exist or may be emerging (cerebral spinal fluid analysis, which requires a lumbar puncture or simple blood tests), currently amyloid PET is the most-used method, the CMS noted.<\/p>\n\n\n\n<p>The CMS decision was applauded by several national associations. In a statement, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) said that this decision will expand access for patients to a vital nuclear medicine test. SNMMI president <strong>Helen Nadel<\/strong>, MD stated: \u201cThis decision ensures increased accessibility to this crucial nuclear medicine test for eligible patients and facilities the targeted use of new treatments for those who can benefit.\u201d<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>About <\/strong><a href=\"http:\/\/www.positrigo.com\/\"><strong>Positrigo<\/strong><\/a><strong>:<\/strong><\/p>\n\n\n\n<p>Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Zurich, Switzerland, the medical device company was founded in 2018 as a spin-off of ETH Zurich. Positrigo\u2019s technology, development, clinical testing and commercialization has been supported by various private investors, the Swiss government and the European Innovation Council. NeuroLF \u2013 the company\u2019s first device \u2013 is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in assisting the diagnosis of causes of dementias, such as Alzheimer\u2019s disease and other brain related disorders. <\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>October 16, 2023<br \/>\nPositrigo opens US subsidiary to benefit from promising market developments<\/p>\n","protected":false},"author":4,"featured_media":7357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[18],"tags":[],"class_list":["post-7419","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/posts\/7419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/comments?post=7419"}],"version-history":[{"count":0,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/posts\/7419\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/media\/7357"}],"wp:attachment":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/media?parent=7419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/categories?post=7419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/tags?post=7419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}